Marissa Seamon
YOU?
Author Swipe
View article: CRISPR technology for Parkinson’s disease: Recent advancements and ongoing challenges
CRISPR technology for Parkinson’s disease: Recent advancements and ongoing challenges Open
Parkinson’s disease (PD) is a neurodegenerative disorder caused by decreased dopamine, resulting in impaired motor function. Various gene editing methods are used in PD research to understand the disease’s complexity and develop treatments…
View article: Low-Dose Niacin Supplementation Improves Motor Function in US Veterans with Parkinson’s Disease: A Single-Center, Randomized, Placebo-Controlled Trial
Low-Dose Niacin Supplementation Improves Motor Function in US Veterans with Parkinson’s Disease: A Single-Center, Randomized, Placebo-Controlled Trial Open
A six-month double-blind, placebo-controlled randomized study was conducted to ascertain whether low-dose daily niacin supplementation would improve motor symptoms in Parkinson’s disease (PD) patients. A total of 47 PD patients were assign…
View article: Low dose niacin versus placebo in the treatment of Parkinson’s Disease: A Randomized Controlled Trial
Low dose niacin versus placebo in the treatment of Parkinson’s Disease: A Randomized Controlled Trial Open
BackgroundParkinson’s Disease (PD) patients have lower niacin levels compared to their spouses. The main objective was to study low-dose daily niacin supplementation versus placebo on motor symptoms in Parkinson’s disease subjects.MethodsA…
View article: Low Dose Niacin Versus Placebo Treatment for Parkinson's Disease: A Randomized Controlled Trial
Low Dose Niacin Versus Placebo Treatment for Parkinson's Disease: A Randomized Controlled Trial Open
Background Parkinson's Disease (PD) patients have lower niacin levels compared to their spouses. The main objective was to study low-dose daily niacin supplementation on motor symptoms in Parkinson's disease subjects. Methods Forty-Seven P…
View article: Niacin Enhancement for Parkinson’s Disease: An Effectiveness Trial
Niacin Enhancement for Parkinson’s Disease: An Effectiveness Trial Open
We previously reported that individuals with Parkinson’s disease (PD) present with lower vitamin B3 levels compared to controls. It may be related to carbidopa interaction, defective tryptophan metabolism, and stresses of night sleep disor…
View article: Niacin and Butyrate: Nutraceuticals Targeting Dysbiosis and Intestinal Permeability in Parkinson’s Disease
Niacin and Butyrate: Nutraceuticals Targeting Dysbiosis and Intestinal Permeability in Parkinson’s Disease Open
Dysbiosis is implicated by many studies in the pathogenesis of Parkinson’s disease (PD). Advances in sequencing technology and computing have resulted in confounding data regarding pathogenic bacterial profiles in conditions such as PD. Ch…
View article: Niacin for Parkinson's disease
Niacin for Parkinson's disease Open
Parkinson's disease (PD) is a neurodegenerative disease associated with progressive loss of motor function and cognitive decline occurring in 1% of the USA population. There is no cure for PD, and current treatment regimens are directed to…
View article: Niacin Ameliorates Neuro-Inflammation in Parkinson’s Disease via GPR109A
Niacin Ameliorates Neuro-Inflammation in Parkinson’s Disease via GPR109A Open
In this study, we used macrophage RAW264.7 cells to elucidate the molecular mechanism underlying the anti-inflammatory actions of niacin. Anti-inflammatory actions of niacin and a possible role of its receptor GPR109A have been studied pre…
View article: Leptin receptor-expressing neurons in ventromedial nucleus of the hypothalamus contribute to weight loss caused by fourth ventricle leptin infusions
Leptin receptor-expressing neurons in ventromedial nucleus of the hypothalamus contribute to weight loss caused by fourth ventricle leptin infusions Open
Leptin administration into the hindbrain, and specifically the nucleus of the solitary tract, increases phosphorylated signal transducer and activator of transcription 3 (pSTAT3), a marker of leptin receptor activation, in hypothalamic nuc…